Revelation Biosciences Financials
| REVB Stock | USD 0.76 0.01 1.33% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.23 | 2.1829 |
|
|
The essential information of the day-to-day investment outlook for Revelation Biosciences includes many different criteria found on its balance sheet. An individual investor should monitor Revelation Biosciences' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Revelation Biosciences.
Net Income |
|
Revelation | Select Account or Indicator |
Understanding current and past Revelation Biosciences Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Revelation Biosciences' financial statements are interrelated, with each one affecting the others. For example, an increase in Revelation Biosciences' assets may result in an increase in income on the income statement.
Please note, the presentation of Revelation Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Revelation Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Revelation Biosciences' management manipulating its earnings.
Revelation Biosciences Stock Summary
Revelation Biosciences competes with Tff Pharmaceuticals, Eliem Therapeutics, Inhibrx, Enliven Therapeutics, and Molecular Partners. Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company was founded in 2020 and is based in San Diego, California. Revelation Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US76135L1017 |
| CUSIP | 716421102 76135L101 76135L309 76135L507 76135L200 |
| Location | California; U.S.A |
| Business Address | 4660 La Jolla |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.revbiosciences.com |
| Phone | 650 800 3717 |
| Currency | USD - US Dollar |
Revelation Biosciences Key Financial Ratios
| Return On Equity | -2.7 | ||||
| Price To Sales | 2.88 X | ||||
| Gross Profit | 90.91 M | ||||
| EBITDA | (95.21 K) | ||||
| Net Income | (120.25 K) |
Revelation Biosciences Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 22.7K | 4.6M | 2.0M | 5.5M | 12.2M | 11.6M | |
| Retained Earnings | (3.6K) | (2.5M) | (14.5M) | (25.3M) | (25.5M) | (24.2M) | |
| Accounts Payable | 1.6M | 865.9K | 596.3K | 554.2K | 1.4M | 812.7K | |
| Cash | 147.1M | 4.5M | 1.3M | 5.3M | 12.0M | 11.4M | |
| Total Liab | 26.3K | 1.2M | 2.1M | 4.5M | 5.6M | 5.3M | |
| Other Liab | 5.9M | 8.0M | 76.4M | 50.7M | 58.3M | 32.4M | |
| Net Tangible Assets | 234.4M | 273.9M | 3.0M | (7.8M) | (7.0M) | (6.7M) | |
| Other Current Assets | 7.7M | 128K | 637.3K | 73.1K | 155.8K | 148.0K | |
| Total Current Assets | 154.8M | 4.6M | 1.9M | 5.4M | 12.1M | 11.5M | |
| Common Stock | 60.1M | 2.3K | 2.3K | 683.0 | 265.0 | 251.75 |
Revelation Biosciences Key Cash Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Capital Expenditures | 804K | 861K | 526K | 132.0K | 4.0 | 3.8 | |
| Net Income | (3.6K) | (1.6M) | (12.0M) | (10.8M) | (120.3K) | (114.2K) | |
| Investments | (294.9M) | (368.6M) | (132.0K) | 16.2K | 18.6K | 19.5K | |
| Change In Cash | 10.7M | (74.2M) | (3.2M) | 4.0M | 6.7M | 12.3M | |
| Net Borrowings | (8.2M) | (14.4M) | 15K | 750K | 675K | 1.1M | |
| Depreciation | 1.5M | 1.7M | 16.8K | 25.0K | 25.0K | 23.8K | |
| Change To Netincome | 3.0M | 4.7M | 43.8K | (1.0M) | (914.9K) | (869.1K) |
Revelation Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Revelation Biosciences's current stock value. Our valuation model uses many indicators to compare Revelation Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Revelation Biosciences competition to find correlations between indicators driving Revelation Biosciences's intrinsic value. More Info.Revelation Biosciences is rated fifth in return on equity category among its peers. It is rated fourth in return on asset category among its peers . At present, Revelation Biosciences' Return On Equity is projected to increase significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Revelation Biosciences' earnings, one of the primary drivers of an investment's value.Revelation Biosciences Systematic Risk
Revelation Biosciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Revelation Biosciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Revelation Biosciences correlated with the market. If Beta is less than 0 Revelation Biosciences generally moves in the opposite direction as compared to the market. If Revelation Biosciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Revelation Biosciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Revelation Biosciences is generally in the same direction as the market. If Beta > 1 Revelation Biosciences moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Revelation Biosciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Revelation Biosciences' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Revelation Biosciences growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Revelation Biosciences November 30, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Revelation Biosciences help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Revelation Biosciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of Revelation Biosciences based on widely used predictive technical indicators. In general, we focus on analyzing Revelation Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Revelation Biosciences's daily price indicators and compare them against related drivers.
| Information Ratio | (0.11) | |||
| Maximum Drawdown | 34.52 | |||
| Value At Risk | (7.83) | |||
| Potential Upside | 8.97 |
Complementary Tools for Revelation Stock analysis
When running Revelation Biosciences' price analysis, check to measure Revelation Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Revelation Biosciences is operating at the current time. Most of Revelation Biosciences' value examination focuses on studying past and present price action to predict the probability of Revelation Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Revelation Biosciences' price. Additionally, you may evaluate how the addition of Revelation Biosciences to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |